Table 4 Antidiabetic and antihypertensive therapy by HbA1c and SBP targets at the six-month follow-up
Antidiabetic therapy | HbA1c ≤ 6.5% | HbA1c > 6.5% to ≤ 7.0% | HbA1c >7.0% to ≤ 7.5% | p-value at 6 mo* | |||
|---|---|---|---|---|---|---|---|
6 mo | ∆BL | 6 mo | ∆BL | 6 mo | ∆BL | ||
Metformin (%) | 78.1 | -0.6 | 80.9 | -0.6 | 80.3 | +0.9 | <0.05 |
Sulfonylureas (%) | 15.8 | +0.6 | 19.1 | -0.3 | 21.7 | +0.1 | <0.0001 |
Alpha-glucosidase inhibitors (%) | 1.0 | 0.0 | 1.6 | +0.1 | 0.8 | -0.2 | <0.05 |
DPP-4 inhibitors (%) | 58.4 | -0.6 | 66.7 | +0.3 | 61.1 | -2.2 | <0.0001 |
Glinide (%) | 2.5 | +0.2 | 3.7 | -0.1 | 6.6 | +0.4 | <0.0001 |
Short-acting insulin (%) | 4.6 | +0.9 | 5.3 | +1.3 | 8.7 | +2.0 | <0.0001 |
Long-acting insulin (%) | 10.3 | +1.8 | 17.4 | +2.7 | 21.7 | +4.1 | <0.0001 |
Mixed insulin (%) | 0.9 | +0.2 | 2.2 | +0.3 | 3.7 | +0.8 | <0.0001 |
≥2 drugs (%) | 60.9 | +0.3 | 74.9 | +1.5 | 78.2 | +0.8 | <0.0001 |
Antihypertensive therapy | SBP ≤ 130 mmHg | SBP > 130 to ≤ 135 mmHg | SBP > 135 to ≤ 140 mmHg | p-value at 6 mo* | |||
6 mo | ∆BL | 6 mo | ∆BL | 6 mo | ∆BL | ||
ACE inhibitors (%) | 50.9 | -0.4 | 53.2 | -0.8 | 54.2 | -0.1 | 0.08 |
ARBs (%) | 28.1 | +0.4 | 28.9 | +0.5 | 27.8 | +0.5 | 0.73 |
Aliskiren (%) | 0.4 | -0.1 | 0.5 | 0.0 | 0.3 | -0.1 | 0.74 |
Betablockers (%) | 48.4 | +0.6 | 47.8 | +0.6 | 47.6 | +0.7 | 0.87 |
Calcium blockers (%) | 25.7 | +0.6 | 29.3 | +0.8 | 31.8 | +1.0 | <0.0001 |
Diuretics (%) | 42.7 | +0.4 | 42.9 | +0.2 | 47.8 | +1.3 | <0.01 |
Other (%) | 8.9 | +0.2 | 10.5 | +0.4 | 12.8 | +0.1 | <0.001 |
≥2 drugs (%) | 63.3 | +0.6 | 68.4 | +0.3 | 70.0 | +1.5 | <0.0001 |